Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial

Amini, Paryan; Sajedi, Firozeh; Mirjalili, Mahtabalsadat; Mohammadi, Younes; Mehrpooya, Maryam

doi:10.1007/s00228-022-03407-x

Cited by 6 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal findings of this narrative review support the hypothesis that diabetic individuals with PDN may benefit from antioxidant and anti-inflammatory supplements such as vitamin E [39][40][41], B-complex [26][27][28][29][30][31][32], omega-3 fatty acids [13], CoQ10 [25], and N-acetylcysteine [38]. These findings further our understanding of how nutrition may contribute to diabetic foot ulcers [42][43][44].…”

Section: Discussionsupporting

confidence: 65%

“…In a randomised controlled trial (RCT) [25], at the end of week 8, the decrease in mean pain 11-point numeric rating scale (NRS) and in the pain-associated sleep interference score (SIS) was superior among participants receiving CoQ10/pregabalin vs. controls (p < 0.001) (▶ table 1).…”

Section: Coenzyme Q-10mentioning

confidence: 99%

“…CoQ10 may help protect nerve cells from injury and relieve neuropathic pain in people with PDN by lowering oxidative stress and inflammation. While some studies have yielded encouraging findings[25], the evidence is still deemed limited. Overall, while the preliminary evidence on CoQ10 and PDN is promising, further high-quality research is required to better understand its potential advantages, appropriate dose, and long-term safety in PDN therapy.The antioxidant and anti-inflammatory characteristics of N-acetylcysteine support a potential role in PDN.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review

Apergi,

Papanas

2023

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Painful diabetic neuropathy (PDN) is a serious and very common complication of diabetes mellitus (DM). It negatively affects the quality of life, increases morbidity and poses a financial burden on the health care system. Currently, treatment of PDN focuses on glycaemic control, while pathogenesis-oriented therapy has not yielded satisfactory results. The need to improve therapy remains. There is accumulating evidence on the potential benefit of nutritional interventions. The aim of this narrative review was to examine the potential benefit of dietary and nutritional supplementation for PDN management. According to preliminary research, supplementation with vitamin E, B-complex, omega 3 fatty acids, CoQ10 or N-acetylcysteine appears to yield promising results in improving PDN symptoms.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Coenzyme Q-10mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review

Apergi,

Papanas

2023

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Raygan et al reported that CoQ10 was helpful in assessing insulin resistance homeostasis model and homeostasis model assessment-β cell function in diabetic patients (Raygan et al, 2016). These researches confirmed the capability of CoQ10 to slow down the progression of diabetes (Yoo and Yum, 2018) and to alleviate the complication symptoms in patients with T2DM (Tabatabaei-Malazy et al, 2019;Amini et al, 2022).…”

Section: Introductionmentioning

confidence: 85%

Investigation of anti-diabetic effect of a novel coenzyme Q10 derivative

Tan,

Yang,

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Introduction: The rising incidence of type 2 diabetes has seriously affected international public health. The search for more drugs that can effectively treat diabetes has become a cutting-edge trend in research. Coenzyme Q10 (CoQ10) has attracted much attention in the last decade due to its wide range of biological activities. Many researchers have explored the clinical effects of CoQ10 in patients with type 2 diabetes. However, CoQ10 has low bio-availability due to its high lipophilicity. Therefore, we have structurally optimized CoQ10 in an attempt to exploit the potential of its pharmacological activity.Methods: A novel coenzyme Q10 derivative (L-50) was designed and synthesized by introducing a group containing bromine atom and hydroxyl at the terminal of coenzyme Q10 (CoQ10), and the antidiabetic effect of L-50 was investigated by cellular assays and animal experiments.Results: Cytotoxicity results showed that L-50 was comparatively low toxicity to HepG2 cells. Hypoglycemic assays indicated that L-50 could increase glucose uptake in IR-HepG2 cells, with significantly enhanced hypoglycemic capacity compared to the CoQ10. In addition, L-50 improved cellular utilization of glucose through reduction of reactive oxygen species (ROS) accumulated in insulin-resistant HepG2 cells (IR-HepG2) and regulation of JNK/AKT/GSK3β signaling pathway, resulting in hypoglycemic effects. Furthermore, the animal experiments demonstrated that L-50 could restore the body weight of HFD/STZ mice. Notably, the findings suggested that L-50 could improve glycemic and lipid metabolism in HFD/STZ mice. Moreover, L-50 could increase fasting insulin levels (FINS) in HFD/STZ mice, leading to a decrease in fasting blood glucose (FBG) and hepatic glycogen. Furthermore, L-50 could recover triglycerides (TG), total cholesterol (T-CHO), lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) levels in HFD/STZ mice.Discussion: The addition of a bromine atom and a hydroxyl group to CoQ10 could enhance its anti-diabetic activity. It is anticipated that L-50 could be a promising new agent for T2DM.

show abstract

“…Iran, 2021 [57] The limited clinical efficacy of CoQ10 observed in several studies may be attributed to its low oral bioavailability and short duration of therapy, which result in low CoQ10 levels in both plasma and tissues and thus hinder CoQ10 from achieving its therapeutic potential. For instance, in a study involving patients experiencing clinical cardiac arrest, a seven-day course of CoQ10, despite a dosage of 300 mg taken twice daily resulting in increased plasma CoQ10 levels, failed to demonstrate an improvement in neurological and biochemical parameters [58].…”

Section: Efficacy Of Coenzyme Q10 Therapy When Administered Orallymentioning

confidence: 99%

Prospects of Intravenous Coenzyme Q10 Administration in Emergency Ischemic Conditions

Kalenikova,

Gorodetskaya,

Povarova

et al. 2024

Life

View full text Add to dashboard Cite

Coenzyme CoQ10 (CoQ10) is an endogenous lipid-soluble antioxidant that effectively protects lipids, proteins, and DNA from oxidation due to its ability to undergo redox transitions between oxidized and reduced forms. Various oxidative stress-associated infectious and somatic diseases have been observed to disrupt the balance of CoQ10 concentration in tissues. As a high molecular weight polar lipophilic compound, CoQ10 exhibits very limited oral bioavailability, which restrains its therapeutic potential. Nevertheless, numerous studies have confirmed the clinical efficacy of CoQ10 therapy through oral administration of high doses over extended time periods. Experimental studies have demonstrated that in emergency situations, intravenous administration of both oxidized and reduced-form CoQ10 leads to a rapid increase in its concentration in organ tissues, offering protection for organ tissues in ischemic conditions. This suggests that the cardio- and neuroprotective efficacy of intravenously administered CoQ10 forms could present new opportunities in treating acute ischemic conditions. Based on these findings, the review provides reasoning supporting further research and implementation of CoQ10 dosage forms for intravenous administration in emergency situations into clinical practice.

show abstract

Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial

Cited by 6 publications

References 41 publications

Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review

Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review

Investigation of anti-diabetic effect of a novel coenzyme Q10 derivative

Prospects of Intravenous Coenzyme Q10 Administration in Emergency Ischemic Conditions

Contact Info

Product

Resources

About